ClinicalTrials.gg
Not yet recruitingNCT07603531EDYDES-maintUpdated Jun 1, 2026

Assessment of the Efficacy of the Dynamic Decongestive System in the Maintenance Phase of Lower Limb Lymphedema

An interventional study of Control group: Currently available compression devices and DDS group: Dynamic compression device (DDS) in Lymphedema Lower Extremity, sponsored by Jean-Paul Belgrado. Not yet recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Jean-Paul Belgrado · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Lymphedema with a site in France — 6 open to participants now, 6 under way, none of them phase 3. Lymphedema · France.

Planned enrollment
6th of 18
98 · median 53
Started
2026
with 1 other
No phase
17 of 29
5 open now
Registered
28th of 29
by date
Lead sponsor
2 of 29
Jean-Paul Belgrado

Among the 29 studies in Lymphedema with a site in France, this one is the 6th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2026, is one of 17 with no phase, and was the 28th registered.

Lymphedema

529 studies on the registry are indexed under Lymphedema; 129 are open to participants now.

Browse Lymphedema studies →

Open to participants now

6 of the 29 studies in Lymphedema with a site in France are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 84 Lymphedema studies recruiting now, 46 (55%) set no upper age limit and 21 (25%) stop at 75 or younger; 5 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Lymphedema with a site in France, or all of them as a file.
02

Study summary

The trial aims to determine whether the dynamic compression device, used in combination with elastic compression garments, is non-inferior to currently available compression devices (CACD) during the maintenance phase of lower-limb lymphoedema treatment.

This is a two-arm, parallel-group trial. Both groups will include patients being discharged after the inpatient intensive treatment phase for lower-limb lymphoedema. Eligible participants will be enrolled on the afternoon of their final inpatient treatment day, prior to discharge.

Participants will be allocated to one of the following groups:

DDS group: elastic compression garment worn at least during the day and as often as possible during the night, according to patient preference and expert advice, plus DDS use for a minimum of 2 hours at the end of the day, used alone without an elastic garment.

Control group: elastic compression garment worn at least during the day and as often as possible during the night, according to patient preference and expert advice, plus currently available compression devices, including multicomponent bandages, pneumatic compression devices, and compression wraps, according to patient preference and the center's recommendations.

Manual lymphatic drainage will be permitted in both groups.

Patients will undergo three assessment visits:

Visit 1 / Baseline-Inclusion (V1): afternoon of the final inpatient treatment day, prior to discharge from intensive treatment; Visit 2 (V2): end of week 6, ± 7 days; Visit 3 (V3): end of week 12, ± 7 days.

Read the detailed description

Background:

Lymphedema is a chronic, progressive condition characterized by impaired lymphatic drainage, leading to the accumulation of protein-rich fluid in the interstitial tissues, progressive tissue remodeling, and an increased risk of complications such as infection. Although lymphedema is not curable, standard management combining intensive decongestive therapy followed by lifelong maintenance treatment can significantly reduce limb volume, improve function, and enhance quality of life. However, maintaining long-term disease control remains challenging.

The maintenance phase relies primarily on compression therapy and patient self-management. Adherence is often suboptimal due to treatment complexity, cost, limited access to specialized care, and the impact of therapy on daily activities. As a result, patients frequently experience recurrent edema, functional impairment, and infectious complications such as cellulitis, contributing to a substantial clinical and socioeconomic burden.

Current standard approaches, including multicomponent bandaging and elastic compression garments, are effective but have important limitations. Multicomponent bandaging is highly operator-dependent, time-consuming, and difficult to maintain because frequent adjustments are required as limb volume changes. Elastic compression garments, while more practical, may be insufficient to achieve sustained decongestion, particularly in patients with moderate-to-severe disease. Overall, existing therapies often fail to provide consistent long-term edema control in real-world settings.

Recent technological advances have enabled the development of dynamic compression systems designed to improve usability and treatment consistency.

The Dynamic Decongestion System (DDS) is designed to standardize compression delivery, reduce operator dependency, and support patient autonomy in the home setting. This study aims to evaluate the clinical relevance of DDS as an adjunct to standard maintenance therapy in patients with primary or secondary lymphedema who have completed intensive decongestive treatment, with the objective of improving long-term volume control and reducing the overall burden of disease.

03

Conditions studied

  • Lymphedema Lower Extremity

Browse trials for

Keywords

  • Complex decongestive therapy
  • Dynamic compression
  • Non-inferiority trial
  • Lymphoedema maintenance treatment
  • Limb volume reduction
  • Limb volume maintenance
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Men and women
  • Unilateral lower limb lymphedema of stage II or III according to the criteria defined by the International Society of Lymphology
  • Patients completing an inpatient intensive treatment phase, including patients participating in CIV-25-01-050914, with a minimum of 20% of excess volume reduction
  • Patients who have given their freely and signed it prior to any intervention in the study.
  • Patients with a morphology compatible with the perimetric coverage of the device (calf and thigh).
  • Patients able to use the device
  • Patients enrolled in a social security plan or covered by similar health insurance.

Exclusion criteria

Exclusion Criteria:

  • Patients with suspended lymphoedema of the thigh (unaffected calf and foot)
  • Patients with lipedema
  • Patients with bilateral lower limb lymphoedema
  • Patients with a lymphedema associated with active cancer requiring acute chemotherapy, or oncologic relapses, or treatment in progress
  • Patients with for compression on the lower limbs such as stent/arterial graft in the area under compression
  • Peripheral artery disease ABI ≤ 0.6
  • Advanced diabetic microangiopathy
  • Active deep/superficial active or recent venous thrombosis, phlegmasia ceruela dolens (painful blue inflammation), active venous leg ulcers, septic/acute thrombophlebitis of the limb (in the last 6 months)
  • A condition where increased venous or lymphatic return is undesirable
  • Neurological disease (including neurogenic diabetic foot, severe peripheral neuropathy of the limb)
  • Pulmonary embolism (last 6 months), pulmonary edema, poorly controlled asthma
  • Cardiac insufficiency (compensated or decompensated)
  • Implantable stimulation devices such as pacemaker
  • Chronic kidney disease with acute renal failure
  • Open skin lesions or skin and subcutaneous infection (cellulitis, erysipelas, lymphangitis, etc.)
  • Skin atrophy of the limb
  • Bullous dermatoses
  • Presence of subcutaneous osteosynthesis material with an external component lying subdermally at the level of the treated lower limb
  • Hyperalgesia of the foot, knee or hip
  • Patients with a known allergy to the components used in the device
  • Patients with psychiatric, psychological, or neurological disorders
  • Patients with impaired cognitive or motor skills and dependent individuals
  • Patients participating in another clinical trial
  • Pregnant or breastfeeding women. Women of will undergo Clearblue® urine pregnancy testing prior to enrollment to verify eligibility.
  • Vulnerable patients, adults being the object of a legal protective measure or unable to express their consent
  • Patients unable to submit to the constraints of the protocol
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
98 participants (estimated)

Study arms

  • Active comparator
    Control group: Currently available compression devices

    Control group: Currently available compression devices Patients in the control group will structure the maintenance phase treatment of their lower limb lymphoedema depending on personal preferences and the recommendations of their treating physician(s).

    Device: Control group: Currently available compression devices

  • Experimental
    DDS group: Dynamic compression device (DDS)

    Patients in the DDS group will structure the maintenance phase of thier lower limb lymphodema treatment depending on their personal preferences and the recommendations of their treating physician(s).

    Device: DDS group: Dynamic compression device (DDS)

Interventions

  • DeviceControl group: Currently available compression devices

    Participant in the control group may use all currently available compression devices to treat their lymphoedema, in addition to the prescribed elastic garment(s).

  • DeviceDDS group: Dynamic compression device (DDS)

    Patients in the DDS group are limited to using the DDS device for a minimum of 2h at the end of the day as an adjuvant compression modality to the prescribed elastic garment(s).

06

What researchers measure

Primary outcomes

  1. Relative excess limb volume (%)

    Change in relative excess limb volume (%) of the affected limb from baseline (Day 0) to the end of the 12-week maintenance phase treatment, based on circumferential tape measurements.

    Time frame: 12 weeks

Secondary outcomes

  1. Longitudinal change in excess volume of the affected limb in ml

    Excess limb volume changes will be measured in ml using three distinct methods: 1. circumferential tape measurements; 2. opto-electric volumetry; 3. 3D scanner.

    Time frame: 12 weeks

  2. Longitudinal change in the volume of the feet in ml

    assessed by water volumetry (ValGrado method)

    Time frame: 12 weeks

  3. Dermal and subcutaneous tissue thickness in mm

    assessed by ultrasound imaging

    Time frame: 12 weeks

  4. Compressibility of the skin and subcutaneous tissue in mm

    assessed by ultrasound imaging under standardized weight

    Time frame: 12 weeks

  5. Viscoelasticity of the skin and subcutaneous tissue complex

    Viscoelasticity of the skin and subcutaneous tissue will be assessed using a handheld, non-invasive myotonometer (Myoton PRO). The device delivers a brief, low-force mechanical impulse through a probe placed on the skin and records the resulting damped oscillation of the underlying tissues, from which a quantitative viscoelasticity index is derived.

    Time frame: 12 weeks

  6. Skin temperature of the affected limb (in C°)

    based on far infrared thermography mapping

    Time frame: 12 weeks

  7. Lower limb contour changes

    based on standardized photos and measurements of surface area in cm2

    Time frame: 12 weeks

  8. Depth of the pitting sign in mm

    based on standardized measurements

    Time frame: 12 weeks

  9. Incremental cost-effectiveness ratio (ICER) of DDS versus CATP

    Cost-effectiveness will be evaluated by calculating the incremental cost-effectiveness ratio (ICER) of DDS versus CATP over 12 weeks. The ICER will be defined as the difference in mean total cost per participant between DDS and CATP, divided by the difference in mean quality-adjusted life-years (QALYs) per participant, with QALYs derived from EQ-5D-5L utility scores collected during the study. A lower ICER (or dominance of one strategy) will indicate a more cost-effective option. Unit of Measure Cost per QALY gained

    Time frame: 12 weeks

  10. Frequency of infectious episodes

    collected via an ePROM on a weekly basis and by the investigator at V1, V2 and V3, including: * Non-necrotizing dermo-hypodermitis * Lymphangitis

    Time frame: 12 weeks

  11. Patient-reported quality of life

    Lymphedema-specific quality of life will be assessed using the Lymphoedema Quality of Life Questionnaire - Leg (LYMQOL-Leg), a validated, limb-specific patient-reported outcome measure for lower-limb lymphedema. The questionnaire includes multiple items covering domains such as function, appearance, symptoms, and mood, each rated on an ordinal scale; domain scores and an overall quality-of-life score are calculated by summing item responses. Scores typically range from a minimum of 1 to a maximum of 4 (or 10 for the global numerical rating scale, depending on the scoring convention used), with higher scores indicating a worse quality of life (greater impairment) in the evaluated domain.

    Time frame: 12 weeks

  12. Patient's observance to compression therapy

    Observance to compression therapy will be assessed using a composite measure based on device-recorded wear time from the investigational compression system and patient-reported use of all compression modalities (DDS device, bandages, garments, and other devices) collected through electronic patient-reported outcome questionnaires and/or patient diaries at week 6 (V2) and week 12 (V3). For each participant, the main adherence metric will be the percentage of prescribed daily wear time (hh:mm) achieved for the investigational device and for any other compression systems, separately for daytime and nighttime use.

    Time frame: 12 weeks

  13. Patient comfort with compression therapy

    Patient-reported comfort with compression therapy will be assessed using the International Compression Club Comfort Questionnaire Patient Version (ICC CQ-P), a validated comfort scale administered in both study groups at week 12. The ICC CQ-P total score is calculated as the sum of item responses, ranging from a minimum of 0 (worst comfort) to a maximum of 10 (best comfort).

    Time frame: 12 weeks

  14. Long-term safety questionnaire (ancillary study)

    Long-term safety and patient experience will be assessed in the ancillary follow-up study using a trial-specific electronic patient-reported outcome questionnaire. The questionnaire evaluates multiple domains related to long-term use of the device, including safety events (e.g., local symptoms or adverse effects), device usage patterns, patient satisfaction, adherence to prescribed use, and perceived device durability. The primary outcome will be a composite safety and usability profile derived from these domains, summarized descriptively over time; worse safety/experience is reflected by higher frequencies of device-related adverse events, lower adherence and satisfaction, and more frequent reports of device problems.

    Time frame: Ancillary study data will be collected quarterly for a period of up to three years (corresponding to the estimated lifespan of the device) or until CE-marking, whichever occurs first.

  15. Device-specific comfort, ease of use, and satisfaction (trial-specific questionnaire, DDS group)

    Among participants allocated to the investigational device, device-specific comfort, ease of use, and satisfaction will be assessed at week 12 using a trial-specific patient-reported questionnaire, including a Likert scale, biary responses (Yes/No), and open-ended questions.

    Time frame: 12 weeks

  16. Mean total direct medical cost per participant over 12 weeks

    Direct medical costs related to lymphoedema management will include costs of treatment modalities (manual lymph drainage, pressotherapy, mechanical devices, medications, skin care), lymphoedema-related healthcare consultations, hospitalizations and diagnostic procedures, and medical devices used during the 12-week period. For each participant, all relevant resource items will be recorded and valued using appropriate unit costs. For each treatment arm, the mean total direct medical cost per participant and standard deviation will be reported. Unit of Measure Currency units per participant (e.g. EUR per participant)

    Time frame: 12 weeks

  17. Number of lymphoedema treatment sessions per participant over 12 weeks

    Use of lymphoedema treatment modalities (manual lymph drainage, pressotherapy, mechanical devices, medications, skin care) will be recorded over 12 weeks, including frequency and duration of each treatment session and location (at home or outside the home). For each treatment arm, the mean number of treatment sessions per participant (by modality) and mean duration per session will be reported. Unit of Measure Number of sessions per participant

    Time frame: 12 weeks

  18. Number and cost of medical devices used per participant over 12 weeks

    All medical devices used for lymphoedema management during the 12-week period (including DDS or CATP and any additional devices) will be recorded. For each participant, the number of devices used and their associated costs will be documented. For each treatment arm, the mean number of devices per participant and mean device cost per participant will be reported. Unit of Measure Number of devices per participant and currency units per participan

    Time frame: 12 weeks

  19. Mean out-of-pocket cost per participant over 12 weeks

    Out-of-pocket costs borne by participants will include transportation costs (mode of transport, number of journeys, distance between home and hospital, travel time) and co-payments related to lymphoedema care. For each participant, all self-reported out-of-pocket expenses over the 12-week period will be recorded and summed. For each treatment arm, the mean total out-of-pocket cost per participant and standard deviation will be reported. Unit of Measure Currency units per participant

    Time frame: 12 weeks

  20. Number of lymphoedema-related healthcare consultations and hospitalizations per participant over 12 weeks

    Lymphoedema-related healthcare professional (HCP) resource use will include consultations with physiotherapists, nurses, lymphoedema specialists and other relevant HCPs, as well as hospitalizations. For each participant, the number of consultations (by HCP category), reasons for consultations, and the number and duration of hospitalizations will be recorded. For each treatment arm, the mean number of consultations and hospitalizations per participant and mean length of stay will be reported. Unit of Measure Number of events per participant

    Time frame: 12 weeks

Other outcomes

  1. Safety outcome: Number of participants with adverse events and device-related safety issues over 12 weeks

    The safety of the devices used in both groups will be assessed by counting the number of participants who experience at least one adverse event (AE), serious adverse event (SAE), adverse device effect (ADE), serious adverse device effect (SADE), device deficiency (DD), or serious/unexpected serious adverse reaction (S/USAR) during the study. Events will be summarized by category (AE, SAE, ADE, SADE, DD, S/USAR), severity, and relationship to the investigational device for each treatment arm. All untoward events will be collected by investigators during the intervention and follow-up periods and by participants through their patient diaries. Unit of Measure Number of participants

    Time frame: 12 weeks

  2. Exploratory objectives: Assess the coherence between three volumetric methods

    This exploratory outcome will assess the coherence between different tools used to quantify limb volume in lymphedema. The analysis will compare volume measurements obtained from a 3D scanner (EinStar VEGA), circumferential tape measurements, and a Perometer to evaluate the degree of correlation and agreement between these methods.

    Time frame: 12 weeks

  3. Exploratory coherence between methods of assessing skin and subcutaneous tissue thickness

    This exploratory outcome will assess the coherence between different modalities used to evaluate skin and subcutaneous tissue thickness (mm). The analysis will compare measurements obtained from ultrasonography, compressibility assessment, and the pitting test to determine the degree of correlation and agreement between these methods.

    Time frame: 12 weeks

  4. Exploratory objective: To assess the coherence between data registered by the DDS integrated sensor system and clinical measurements.

    This exploratory outcome will assess the coherence between data recorded by the integrated sensor system of the investigational compression device and selected clinical and patient-reported measures. The analysis will compare device-recorded signals with (1) tissue stiffness values obtained using a handheld myotonometer (MyotonPro), (2) limb volume estimates derived from circumferential tape measurements, and (3) weekly questionnaire responses in the adherence/observance domain. Coherence will be examined using correlation and agreement analyses to determine how closely sensor-derived data reflect these external measures.

    Time frame: 12 weeks

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Jun 2027, 11 months later.

Of 175 non-industry interventional studies with no phase under Lymphedema, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 68. This study's planned 11 months is below that.

Counting every sponsor, half of 197 studies reached it within 25 months; a quarter within 11 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2026
First posted
May 22, 2026
StartEst.
Jul 1, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07603531
Lead sponsor
Jean-Paul Belgrado
Responsible party
Jean-Paul Belgrado (Professor, Coordinator of the Lymphology and Rehabilitation Research Unit, Université libre de Bruxelles (ULB), Université Libre de Bruxelles) — Sponsor-investigator
First posted
May 22, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Jun 1, 2026

Study contacts

Prof. Jean-Paul Belgrado, PhD
Contact
jp.belgrado@gmail.com
+33 6 38 39 79 56
Velika V Stoitchkova, MSc
Contact
velika.stoichkova@gmail.com
+359 882 40 55 33

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion